Clinical Trial Update: Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 clinical trial is evaluating Purinostat Mesylate in combination with pomalidomide and low-dose dexamethasone in relapsed or refractory multipl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Pomalidomide (Pomalidomide)
• Purinostat Mesylate (Purinostat Mesylate)

Snippet

Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd | Conditions: Relapsed or Refractory Multiple Myeloma (RRMM) | Phase 1, Phase 2 | Status: RECRUITING